Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12th 2021

In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.

Axi-Cel Provides Durable Responses in Higher-Risk Follicular Lymphoma and MZL, Regardless of POD24 Status

June 11th 2021

Axicabtagene ciloleucel demonstrated significant clinical activity with durable responses in patients with relapsed/refractory indolent non-Hodgkin lymphoma who experienced disease progression within 24 months from initiation of the first anti-CD20–containing chemotherapy, which is a high-risk clinical feature.

Lenalidomide/Rituximab Continues to Improve PFS in iNHL, MCL

June 11th 2021

The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

C-CAR039 Demonstrates Promising Efficacy, Safety in Relapsed/Refractory B-NHL

June 8th 2021

The second-generation 4-1BB bi-specific CAR T-cell therapy C-CAR039 improved response rates and showed favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Mosunetuzumab-Polatuzumab Vedotin Combo Effective, Well Tolerated in R/R B-NHL

June 5th 2021

Two cases of cytokine release syndrome occurred during the first cycle of step-up dosing; however, both were considered non-severe and were treated without the need of tocilizumab, admission to the ICU or use of vasopressors.

Dr. Lunning on the Efficacy of Axi-Cel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

June 2nd 2021

Matthew Lunning, DO, discusses the efficacy of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Loncastuximab Tesirine Provides Alternative for Broad Range of Patients With DLBCL

June 1st 2021

Loncastuximab tesirine-lpyl (Zynlonta) exhibited significant clinical activity, including impressive response rates with tolerable safety, as a single agent in adult patients with relapsed/refractory large B-cell lymphoma that failed prior established therapies.

New DLBCL Treatments Are Poised to Fill an Unmet Need for Patients in Challenging Settings

May 26th 2021

During a recent OncLive Peer Exchange®, a panel of lymphoma experts discussed tafasitamab-cxix, polatuzumab vedotin-piiq, and selinexor, and how and when they use them for their patients with diffuse large B-cell lymphoma.

FDA Accepts BLA for Ublituximab/Umbralisib in CLL and SLL

May 25th 2021

The FDA has accepted a biologics license application for ublituximab in combination with umbralisib in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia.

FDA Grants Priority Review to Zanubrutinib for Marginal Zone Lymphoma

May 19th 2021

The FDA has granted priority review to a supplemental new drug application for zanubrutinib as a treatment option for adult patients with marginal zone lymphoma who have previously received at least 1 anti-CD20–based therapy.

Loncastuximab Tesirine Showcases Substantial Antitumor Activity in Heavily Pretreated Relapsed/Refractory DLBCL

May 18th 2021

Loncastuximab tesirine-lypl has demonstrated significant antitumor activity with durable responses and an acceptable toxicity profile, when used as a monotherapy in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma.

FDA Lifts Partial Clinical Hold on Odronextamab Studies in Follicular Lymphoma and DLBCL

May 18th 2021

The FDA has lifted a partial clinical hold that had been placed on the enrollment of patients with follicular lymphoma and diffuse large B-cell lymphoma to monotherapy trials examining the bispecific antibody odronextamab.

Dr. Matasar on the Rationale for Combining Copanlisib and Rituximab in Indolent NHL

May 13th 2021

Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.

High Pretreatment ctDNA Levels Correlate With Short Diagnosis-to-Treatment Intervals in DLBCL

May 12th 2021

Pretreatment circulating tumor DNA levels were found to more objectively measure disease burden compared with diagnosis-to-treatment intervals in patients with diffuse large B-cell lymphoma and can therefore be used to quantify and mitigate selection bias in prospective DLBCL clinical trials.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Loncastuximab Tesirine-Ipyl Added to NCCN Guidelines for B-Cell Lymphomas

May 6th 2021

The recently FDA-approved loncastuximab tesirine-lpyl has been added to the latest National Comprehensive Cancer Network Clinical Practice Guidelines for B-cell lymphomas.

Dr. D’Angelo on Selecting CAR T-Cell Therapy or Transplantation in DLBCL

May 4th 2021

Christopher R. D’Angelo, MD, discusses factors that determine whether CAR T-cell therapy or autologous stem cell transplant should be used in patients with relapsed/refractory diffuse large B-cell lymphoma.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.